Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2. The crystal structure of the IL2v-IL-2Rβγ complex was determined and CEA-IL2v activity was assessed using human immune effector cells. Tumor targeting was investigated in tumor-bearing mice using 89Zr-labeled CEA-IL2v. Efficacy studies were performed in (a) syngeneic mouse models as monotherapy and combined with anti-PD-L1, and in (b) xenograft mouse models in combination with ADCC-mediating antibodies. CEA-IL2v binds to CEA with pM avidity but not to CD25, and consequently did not preferentially activate Tregs. In vivo, CEA-IL2v demonstrated superior pharmacokinetics and tumor targeting compared with a wild-type IL-2-based CEA immunocytokine (CEA-IL2wt). CEA-IL2v strongly expanded NK and CD8+ T cells, skewing the CD8+:CD4+ ratio toward CD8+ T cells both in the periphery and in the tumor, and mediated single agent efficacy in syngeneic MC38-CEA and PancO2-CEA models. Combination with trastuzumab, cetuximab and imgatuzumab, all of human IgG1 isotype, resulted in superior efficacy compared with the monotherapies alone. Combined with anti-PD-L1, CEA-IL2v mediated superior efficacy over the respective monotherapies, and over the combination with an untargeted control immunocytokine. These preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, the therapeutic activity of these mAbs correlates with the abundance of NK cells, is influenced by genetic polymorphisms affecting Fc g R functions, and can be boosted (at least preclinically) by immunotherapeutic interventions preventing NK dysfunction (e.g., IL2 or IL12 administration) (Gennari et al., 2004; Jaime-Ramirez et al., 2011; Klein et al., 2017; Kono et al., 2002; Musolino”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Klein et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“redesign the next generation cytokines for therapeutic purposes, which are currently being tested and have shown beneficial effects in combination with ICB in preclinical studies”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Klein et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400 · cited 1×
“It interferes with the immune episode of cancer cells by interacting with the inhibitory PD-1 receptor on T cells.(42) In vitro studies showed that CEA-IL2v induces PD-L1 upregulation on tumor cells (Fig.”
BackgroundA function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819 · cited 2×
“constitutively expressed on CD4CFoxP3C Tregs.(7) (Fig.”
InfluentialThe role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657 · cited 1×
“binding, whereas the b and the g subunits mediate signal transduction.(3,4,6) IL-2Rbg is expressed on NK cells, monocytes, macrophages and resting CD4C and CD8C T cells, while IL-2Rabg”
BackgroundIL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289 · cited 1×
“In addition, systemic IL-2 treatment has been associated with severe cardiovascular, pulmonary, hepatic, gastrointestinal, neurologic and hematological side effects, such that it is only given to patients at specialized centers.(10) Preclinical experiments showed that IL-2-induced pulmonary edema is caused by interact…”
BackgroundPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178 · cited 1×
“binding, whereas the b and the g subunits mediate signal transduction.(3,4,6) IL-2Rbg is expressed on NK cells, monocytes, macrophages and resting CD4C and CD8C T cells, while IL-2Rabg”
BackgroundSelective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 870 · cited 1×
“IL-2-antibody complexes that no longer interact with CD25 and caused a strong preferential expansion of CD8C T-memory over CD4C T cells.(41) In a separate study, the kinetics of CD8C and NK cell proliferation following treatment with muCEA-IL2v was compared with muCEA-IL2wt.”
ResultConlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
Thompson, J. A., Grunert, F., & Zimmermann, W. (1991) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860050510 · Cited by 608 · cited 1×
“95% of colorectal, 90% of pancreatic, 80% of gastric, 60% of non-small cell lung and 40% of breast cancer specimens staining positive for CEA with moderate or high intensity (data not shown), whereas in normal tissues only low-level CEA expression is found on the apical surface of glandular epithelia in the gastrointe…”
BackgroundExploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552 · cited 1×
“ing to improved antitumor responses, and elicited less expansion of Tregs and reduced pulmonary edema.(45)”
Background
Research works printed but not linked: 6
- Kasprzak A, 2007, Folia Morphol (Warsz), 66, 159
- 10.1158/1078-0432.CCR-15-1696 · DOI · Paper page
- Van Dongen GA, 2015, Q J Nucl Med Mol Imaging, 59, 18
- Clarke P, 1998, Cancer Res, 58, 1469
- Losey HC, 2001, Cancer Res 2015, 75
- Perk LR, 2005, J Nucl Med, 46, 1898
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
“Both versions are currently in clinical development [151, 152].”
Background
Metadata
- Authors
- Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., Neumann, S., de Vera Mudry, M. C., Hinton, H., Crameri, F., Saro, J., Evers, S., Gerdes, C., Bacac, M., van Dongen, G., Moessner, E., & Umaña, P.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
- Roche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Roche Pharma AG (Germany) (DE)
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
- Corresponding author
- Klein, Christian
- Umaña, Pablo
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-01-11
- Volume
- 6
- Issue
- 3
- Pages
- e1277306
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5384349
- OpenAlex
- W2572762406
- Cited by
- 281
- References
- 68
- Citations by year
- 2026: 21 · 2025: 35 · 2024: 39 · 2023: 31 · 2022: 27 · 2021: 40 · 2020: 26 · 2019: 33 · 2018: 20 · 2017: 9
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Genentech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immunocytokines, carcinoembryonic antigen, regulatory T cells, tumor targeting, pharmacokinetics, anti-PD-L1 combination therapy, antibody-dependent cellular cytotoxicity, natural killer cells, CD8+ T cells, trastuzumab, cetuximab, combination cancer immunotherapy, tumor-infiltrating lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. https://app.cochat.ai/papers/10.1080/2162402x.2016.1277306
- The paper
- Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., . . . Umaña, P. (2017). Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1277306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.